Climb Bio, Inc. develops therapeutics for patients with immune-mediated diseases. News about Climb Bio centers on its clinical-stage monoclonal antibody pipeline, including budoprutug, an anti-CD19 antibody for B-cell mediated diseases such as primary membranous nephropathy, immune thrombocytopenia and systemic lupus erythematosus, and CLYM116, an anti-APRIL antibody for IgA nephropathy.
Recurring updates include clinical development progress, formulation data, regulatory actions such as FDA Fast Track Designation for budoprutug in primary membranous nephropathy, R&D presentations, business updates and operating results. Company announcements also cover financing activity, governance changes and investor communications tied to its biotechnology development strategy.
Climb Bio (Nasdaq: CLYM) announced two senior hires on Oct 21, 2025: Adam Villa as SVP, Technical Operations and Ashley Jones as SVP, People & Workforce Strategy. The appointments aim to support execution of clinical development for budoprutug and CLYM116 and to improve operational and workforce capabilities.
Climb Bio granted inducement equity awards on Oct 20, 2025: non-statutory stock options to acquire an aggregate of 360,000 shares, exercise price $2.32 (Nasdaq close on Oct 20, 2025), ten-year term, vesting over four years (25% after one year, then monthly over 36 months).
Climb Bio (Nasdaq: CLYM) will present preclinical and clinical data at ASN Kidney Week 2025 in Houston, Nov 6-9, 2025.
CLYM116: preclinical data show the Fc-engineered anti-APRIL mAb promoted APRIL degradation, enhanced antibody recycling and produced deep, durable IgA reduction in models, supporting development for IgA nephropathy (IgAN). Presentation: Poster SA-PO0253 on Nov 8, 2025, 10:00 AM–12:00 PM.
Budoprutug: published Phase 1b long-term follow-up (NCT04652570) in primary membranous nephropathy reported proteinuria control up to 3 years after up to four doses in four patients; three required no further immunosuppression and no clinically significant treatment-related adverse events were observed. Abstracts available on the ASN Kidney Week website.
Climb Bio (NASDAQ:CLYM), a clinical-stage biotechnology company, has appointed Susan Altschuller, Ph.D., MBA as Chief Financial Officer. Dr. Altschuller brings over 20 years of strategic and financial leadership experience, notably serving as CFO of Cerevel Therapeutics until its $8.7B AbbVie acquisition and as CFO of ImmunoGen.
As part of her appointment, Dr. Altschuller received an inducement equity award of 600,000 stock options with a ten-year term, vesting over four years. The company is advancing two key programs, budoprutug and CLYM116, with significant clinical data expected in the coming year.
Climb Bio (NASDAQ:CLYM) has announced promising preclinical data for CLYM116, its novel therapeutic candidate for IgA nephropathy (IgAN). The study demonstrated superior performance compared to first-generation anti-APRIL monoclonal antibody sibeprenlimab, showing a 2-3 times longer half-life and deeper IgA reduction of >70%.
The company plans to initiate Phase 1 trials in Q4 2025, with initial data expected by mid-2026. CLYM116's subcutaneous formulation showed 85% bioavailability with favorable tolerability. The market opportunity is significant, estimated at $10-20 billion in the US alone, with approximately 170,000 patients.
Climb Bio (Nasdaq: CLYM) announced a webcast event scheduled for September 29, 2025, at 8:00 a.m. ET to discuss their CLYM116 program and IgA Nephropathy (IgAN) opportunity. The event will feature renowned nephrologist Dr. Craig E. Gordon alongside the company's management team.
CLYM116, a preclinical-stage monoclonal antibody, targets APRIL protein using a unique 'sweeper' mechanism. This approach may offer best-in-class efficacy with reduced dosing frequency. The company plans to file an IND or CTA for CLYM116 in H2 2025.
The webcast will cover IgAN market opportunities, comparative preclinical data, and development strategies. It will be available through Climb Bio's investor relations website.
Climb Bio (Nasdaq: CLYM), a clinical-stage biotechnology company focused on immune-mediated disease therapeutics, has announced its participation in four major investor conferences in September 2025.
The company will participate in the Cantor Global Healthcare Conference (Sept 5), Baird Global Healthcare Conference (Sept 9), Morgan Stanley Annual Global Healthcare Conference (Sept 10), and Stifel Virtual Immunology and Inflammation Forum (Sept 16). Most events will feature fireside chats or presentations along with one-on-one investor meetings.
Live webcasts will be available through Climb Bio's investor relations website, with replays accessible for 30 days after each event.
Climb Bio (Nasdaq: CLYM), a clinical-stage biotechnology company focused on immune-mediated disease therapeutics, has announced its participation in four major investor conferences in September 2025.
The company will participate in the Cantor Global Healthcare Conference (Sept 5), Baird Global Healthcare Conference (Sept 9), Morgan Stanley Annual Global Healthcare Conference (Sept 10), and Stifel Virtual Immunology and Inflammation Forum (Sept 10). Most events will feature fireside chats or presentations along with one-on-one investor meetings.
Live webcasts will be available through Climb Bio's investor relations website, with replays accessible for 30 days after each event.
Climb Bio (Nasdaq: CLYM) reported Q2 2025 financial results and provided significant pipeline updates. The company has advanced its two key programs: budoprutug, an anti-CD19 monoclonal antibody, and CLYM116, an anti-APRIL antibody.
Key developments include: First patients dosed in both ITP and SLE trials for budoprutug, upcoming initiation of pMN Phase 2 trial, development of a subcutaneous formulation with promising non-clinical data, and advancement of CLYM116 toward clinical development for IgAN. The company appointed Edgar D. Charles, M.D. as Chief Medical Officer.
Financial highlights: $187.4 million in cash and equivalents as of June 30, 2025, with runway through 2027. R&D expenses increased to $6.6 million from $1.0 million year-over-year, while G&A expenses were $4.1 million.
Climb Bio (NASDAQ: CLYM) has granted an inducement equity award to a new employee under its 2025 Inducement Plan, in accordance with Nasdaq Listing Rule 5635(c)(4). The award, granted on May 19, 2025, consists of a non-statutory stock option to purchase 120,000 shares of common stock at an exercise price of $1.27 per share, matching the closing price on Nasdaq Global Market. The option has a ten-year term and vests over four years, with 25% vesting after the first year and the remaining shares vesting in 36 monthly installments, contingent on continued employment.